📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Solara Shareholders Approve Mohanraj Sanjeevi as Whole-time Director with 99.97% Majority
Solara Active Pharma Sciences Limited has announced the successful passage of a special resolution to appoint Mr. Mohanraj Sanjeevi as a Whole-time Director for a three-year term. The resolution received overwhelming support, with 99.97% of the 26.04 million votes cast in favor. Mr. Sanjeevi's remuneration is set at a fixed Rs. 85 lakh per annum plus a variable component of Rs. 15 lakh. This appointment, effective from January 1, 2026, ensures leadership stability for the company's executive operations.
Key Highlights
Special resolution for appointment passed with 99.97% majority (26,032,102 votes in favor).
Mr. Mohanraj Sanjeevi appointed for a 3-year term effective from January 1, 2026, to December 31, 2028.
Total annual remuneration package includes Rs. 85 lakh fixed and Rs. 15 lakh variable pay.
Promoter and institutional investor groups both voted 100% in favor of the resolution.
Overall voter turnout represented 58.64% of the total outstanding shares of the company.
💼 Action for Investors
The high level of shareholder support indicates strong confidence in the executive leadership. Investors should view this as a routine governance step providing management continuity.
Solara Q3 FY26: Growth API Margins at 25% Amid Strategic Review of Ibuprofen Business
Solara reported Q3 FY26 revenue of INR 346 crores, up 10% Q-o-Q, though consolidated gross margins fell to 47% due to headwinds in the base ibuprofen business. The non-ibuprofen 'growth' segment is performing exceptionally well with 56% gross margins and 25% EBITDA margins, significantly outperforming the commodity business. Management has initiated a strategic review of the ibuprofen division, which is currently utilizing only 3,000 tons of its 6,000-ton Pondicherry capacity. The company successfully reduced debt by INR 146 crores (19%) and targets a sub-INR 500 crore debt level by May 2026.
Key Highlights
Revenue grew 10% Q-o-Q to INR 346 crores; EBITDA stood at INR 37 crores with an 11% margin.
Non-ibuprofen growth business achieved high-tier margins of 56% (gross) and 25% (EBITDA).
Ibuprofen capacity utilization remains low at 50% for the Pondicherry plant (3,000 of 6,000 tons).
Debt was reduced by INR 146 crores (19%) during the quarter, aided by rights issue proceeds.
A one-time exceptional cost of INR 6.7 crores was incurred due to the new labor wage code implementation.
💼 Action for Investors
Investors should closely monitor the Q4 announcement regarding the strategic review of the ibuprofen business, as a potential restructuring or hive-off could unlock significant value from the high-margin growth API segment.
Solara Reports Zero Deviation in ₹308.85 Cr Rights Issue Fund Utilization
Solara Active Pharma Sciences has confirmed that there is no deviation or variation in the utilization of ₹308.85 crores raised through its Rights Issue as of December 31, 2025. The company has primarily used the proceeds for debt reduction, with ₹233.61 crores allocated to the repayment or pre-payment of borrowings. Additionally, ₹74.97 crores have been utilized for general corporate purposes out of a total planned allocation of ₹112.24 crores. The Audit Committee and monitoring agency CRISIL have reviewed and approved these statements without any adverse comments.
Key Highlights
Total funds raised through the Rights Issue amounted to ₹308.85 crores as of December 31, 2025.
A significant portion of ₹233.61 crores was utilized for the repayment or pre-payment of outstanding borrowings.
₹74.97 crores were deployed for General Corporate Purposes (GCP), adhering to the 25% cap of gross proceeds.
The company reported zero deviation from the objects mentioned in the Letter of Offer dated May 09, 2024.
A minor balance of ₹0.26 crores remains in the escrow account to be utilized in upcoming quarters.
💼 Action for Investors
Investors should take confidence in the company's disciplined use of capital for debt reduction, which should improve the balance sheet. Monitor upcoming earnings reports to see the positive impact of reduced interest costs on the bottom line.
Solara Q3 FY26 Revenue Up 15% to ₹3,490M; Board to Evaluate Ibuprofen Business Options
Solara reported a 15% YoY revenue growth to ₹3,490 million in Q3 FY26, driven by its high-margin Growth API segment which achieved a 24.7% EBITDA margin. However, the company posted a net loss of ₹174 million as the commodity Ibuprofen business remains a significant drag with negative EBITDA margins of -22.9%. To address this structural challenge, the Board is appointing strategic advisors to evaluate options for the Ibuprofen business and re-assess the previously announced CRAMS split. Debt reduction is on track, with gross debt falling to ₹6,300 million from ₹7,760 million in March 2025.
Key Highlights
Revenue grew 15% YoY to ₹3,490 million, though EBITDA fell 37% YoY to ₹374 million due to Ibuprofen pricing pressures.
Growth API segment (Ex-Ibuprofen) delivered strong performance with 56.3% gross margins and ₹608 million EBITDA.
Ibuprofen base business reported an EBITDA loss of ₹234 million for the quarter, prompting a strategic review.
Gross debt reduced to ₹6,300 million as of December 2025, with a target to reach ₹4,999 million by May 2026.
Board is re-evaluating the CRAMS & Polymers business split scheme with a new roadmap expected next quarter.
💼 Action for Investors
Investors should closely monitor the upcoming strategic roadmap for the Ibuprofen business, as a potential divestment or restructuring could unlock value by isolating the high-growth, high-margin API portfolio.
Solara Active Pharma Q3 Revenue Grows to ₹349 Cr; Net Loss Widens to ₹17.43 Cr
Solara Active Pharma reported a 16% YoY revenue growth to ₹349 crore for Q3 FY26, but the company's financial health remains under significant pressure. The net loss widened to ₹17.43 crore, impacted by a ₹6.75 crore exceptional item related to new labor codes. Concerns persist regarding liquidity as net current liabilities exceed assets by ₹92.44 crore, with accumulated losses reaching ₹329.64 crore. The company is banking on a pending ₹134.99 crore rights issue call to stabilize its capital position.
Key Highlights
Revenue from operations rose to ₹349.00 crore in Q3 FY26 from ₹300.31 crore in Q3 FY25.
Net loss for the quarter stood at ₹17.43 crore versus a profit of ₹8.09 crore in the previous year's corresponding quarter.
Exceptional loss of ₹6.75 crore recorded due to gratuity and compensated absences impact under new labor codes.
Net current liabilities exceed net current assets by ₹92.44 crore as of December 31, 2025.
Company plans to raise ₹134.99 crore through the final call of its pending rights issue to fund operations.
💼 Action for Investors
Investors should exercise caution given the widening losses and the 'going concern' notes regarding liquidity and working capital deficits. The stock's recovery depends heavily on the successful completion of the rights issue and a significant turnaround in operational margins.
Solara Pharma Issues Second Reminder for ₹131.25 First Call Money Payment
Solara Active Pharma Sciences has issued a second reminder notice for the payment of the First Call Money related to its Rights Issue. Shareholders holding partly paid-up shares are required to pay ₹131.25 per share, which includes ₹3.50 towards face value and ₹127.75 towards premium. The payment window is scheduled from February 5, 2026, to February 19, 2026. Upon successful payment, shares will be converted from a paid-up value of ₹3.50 to ₹7.00.
Key Highlights
First Call Money amount is set at ₹131.25 per partly paid-up equity share
Payment period runs for 15 days from February 5, 2026, to February 19, 2026
Failure to pay will result in the forfeiture of shares and any amount already paid
Successful payment upgrades shares to ₹7.00 partly paid-up status under ISIN IN9624Z01022
Payments must be made electronically via the dedicated RTA portal using Net Banking or UPI
💼 Action for Investors
Investors holding partly paid-up shares (ISIN: IN9624Z01014) must complete the payment by February 19, 2026, to prevent the forfeiture of their existing investment. Ensure the payment is made from the registered bank account to avoid rejection.
Solara Appoints Mohanraj S as Whole-Time Director for 3-Year Term
Solara Active Pharma Sciences has announced the appointment of Mr. Mohanraj S as an Additional Executive Director and Whole-Time Director, effective January 1, 2026. The appointment is for a three-year tenure and is subject to shareholder approval via postal ballot. Mr. Mohanraj brings over 30 years of extensive experience in industrial relations and workforce governance, having held senior roles at Mylan Laboratories and Tata Advanced Materials. His expertise in managing complex labor environments and regulatory compliance is expected to support the company's manufacturing operations.
Key Highlights
Appointment of Mr. Mohanraj S as Whole-Time Director for a fixed term of 3 years starting January 2026.
The appointee possesses over 30 years of experience across Pharma, Biotech, and Defence sectors.
Expertise includes negotiating 7-8 long-term union settlements, primarily in the pharmaceutical industry.
Mr. Mohanraj S is not related to any existing Directors or Key Managerial Personnel of the company.
💼 Action for Investors
This is a strategic management appointment aimed at strengthening industrial relations and operational compliance. Investors should view this as a routine governance update with no immediate impact on stock valuation.
Solara Appoints Mr. Mohanraj S as Whole-Time Director for 3-Year Term
Solara Active Pharma Sciences has approved the appointment of Mr. Mohanraj S as an Additional Executive Director and Whole-Time Director, effective January 1, 2026. The appointment is for a three-year tenure and is subject to shareholder approval through a postal ballot. Mr. Mohanraj brings over 30 years of extensive experience in industrial relations and workforce governance, having previously held senior roles at Mylan Laboratories and Tata Advanced Materials. This move appears aimed at strengthening the company's manufacturing operations and labor management frameworks.
Key Highlights
Appointment of Mr. Mohanraj S as Whole-Time Director for a fixed term of 3 years
New leadership role becomes effective from January 1, 2026
Appointee brings over 30 years of experience across Pharma, Biotech, and Defense sectors
Proven track record with 7-8 successful long-term union settlements in the pharmaceutical industry
The board meeting concluded within 10 minutes, reflecting a focused agenda on this appointment
💼 Action for Investors
Investors should view this as a routine leadership reinforcement aimed at operational stability. No immediate action is required, but the appointee's expertise in industrial relations may benefit long-term manufacturing efficiency.